Advanced or Metastatic Breast Cancer clinical trials

Test immunotherapy plus hormone therapy and an AKT blocker

This trial tests whether combining immunotherapy, hormone therapy, and an AKT-blocking drug can control ER-positive advanced breast cancer in women whose cancer is resistant to hormone treatment. It may help shrink tumors and slow disease by targeting several pathways at once.

Targeting limited breast cancer spread with focused therapy

This trial tests whether treating just the few spots where breast cancer has spread (called oligometastases) with radiation or surgery can help control the disease. It is for people whose cancer has spread to 3 or fewer places, each small in size, and who are healthy enough for local treatments.

M108 plus chemo for CLDN18.2-positive stomach cancer

This trial tests a new drug (M108) combined with standard chemotherapy (CAPOX) as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has a specific protein called Claudin 18.2. The goal is to see if adding M108 helps improve outcomes compared to chemotherapy alone.

Genetic testing for underserved cancer patients

This study offers free genetic testing to cancer patients and their healthcare providers. It aims to help people who may not have easy access to genetic testing understand their cancer risk.

Monitoring test for CDK4/6 drugs in metastatic breast cancer

This study follows people with hormone receptor–positive, HER2-negative metastatic breast cancer who are taking CDK4/6 inhibitor treatment (with or without an added blood test called DiviTum®). The goal is to see how well the standard treatment is working and whether DiviTum® (a serum TK1 activity test) can help guide monitoring.

New drug combo vs. chemo for advanced triple-negative breast cancer

This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.

21-gene testing for older breast cancer patients with lymph node spread

This trial looks at using a 21-gene test to guide treatment decisions for women aged 65 or older who have breast cancer that has spread to lymph nodes. It aims to see if this test can help avoid unnecessary chemotherapy in this group.

HER2 vaccine study for high-risk breast cancer

This trial tests a vaccine designed to help the immune system fight remaining HER2-positive breast cancer cells after standard treatment. It is for people who have completed at least six months of HER2-targeted therapy and still have a high risk of the cancer coming back.

Study of NKT5097 for advanced solid tumors

This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.

TIL therapy for advanced colorectal or prostate cancer

This trial tests a new type of immunotherapy that uses your own white blood cells (TILs) to fight advanced colorectal or prostate cancer. You will have surgery to remove a tumor, then your TIL cells are grown in a lab and given back to you along with other treatments to boost your immune system.

Trastuzumab Deruxtecan for first-line HER2-positive advanced breast cancer

This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.

Comparing two schedules of immunotherapy for advanced triple-negative breast cancer

This trial tests whether giving immunotherapy less often (extended dose intervals) works as well as the standard schedule for people with advanced triple-negative breast cancer who have already completed 6 cycles of first-line treatment. It aims to see if a longer break between doses can be just as effective with fewer hospital visits.

Real-world study of breast cancer treatment with pertuzumab biosimilar

This study observes how a biosimilar version of pertuzumab (a targeted breast cancer drug) works in real-world patients. Researchers will track outcomes in patients receiving this drug either before surgery or as a first treatment for advanced breast cancer.

Partial breast radiation versus no radiation after lumpectomy

This trial compares giving radiation only to part of the breast versus not giving radiation at all after breast-conserving surgery. It’s meant for women with early, hormone-driven breast cancer to see if skipping radiation can be safe and reduce treatment burden.

Testing aerosol chemotherapy through the belly for advanced ovarian cancer

This Phase 1 study tests a new way to deliver chemotherapy inside the abdomen (belly) using a pressurized aerosol during a procedure, along with standard blood (IV) chemotherapy. It may help people with advanced ovarian cancer whose tumors have not progressed but are not removable with surgery yet.

Tested 212Pb imaging drug for certain advanced GRPR tumors

This early-phase study tests how safe and tolerable an experimental radiation drug is for adults with certain advanced or metastatic cancers that show a target called GRPR. Doctors will also use special scans to confirm the tumor has the target so the treatment can be delivered to the right place.

Study of a HER3 antibody with cetuximab and possibly docetaxel

This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.

Tumor immune cells plus pembrolizumab for advanced lung cancer

This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.

HWK-007 for advanced solid tumors

This trial tests a new drug called HWK-007, which is designed to target and attack cancer cells while sparing healthy ones. It is for people with specific advanced solid tumors (lung, endometrial, or ovarian cancer) that have not responded well to standard treatments.

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

AI Education Tool for Breast Cancer Patients

This study tests a new computer-based education module created by artificial intelligence to help breast cancer patients understand their diagnosis and treatment options. The goal is to see if this tool helps patients feel more informed and prepared for their care.

Medical cannabis for advanced pancreatic and colorectal cancer

This trial tests whether medical cannabis can help reduce nausea, vomiting, appetite loss, wasting, and pain in people with advanced pancreatic or colorectal cancer who are starting chemotherapy. It's for Minnesota residents only.

Register for metastatic breast cancer patients in Austria

This trial is a non-treatment registry that collects information about people with metastatic breast cancer in Austria. It may help researchers better understand the disease and outcomes over time by tracking real-world patient details.

AMXI-5001 study for advanced cancers that won’t respond

This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.